| MeSH term | MeSH ID | Detail |
|---|---|---|
| Gastroenteritis | D005759 | 4 associated lipids |
| Hypertrophy, Left Ventricular | D017379 | 12 associated lipids |
| Inappropriate ADH Syndrome | D007177 | 4 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Lymphoma, T-Cell | D016399 | 11 associated lipids |
| Cicatrix, Hypertrophic | D017439 | 4 associated lipids |
| Pityriasis | D010915 | 3 associated lipids |
| Hand Dermatoses | D006229 | 5 associated lipids |
| Postoperative Hemorrhage | D019106 | 7 associated lipids |
| Liver Abscess | D008100 | 6 associated lipids |
| Carpal Tunnel Syndrome | D002349 | 3 associated lipids |
| Foot Dermatoses | D005533 | 3 associated lipids |
| Anus Diseases | D001004 | 3 associated lipids |
| Endomyocardial Fibrosis | D004719 | 4 associated lipids |
| Ataxia Telangiectasia | D001260 | 6 associated lipids |
| Herpesviridae Infections | D006566 | 4 associated lipids |
| Leukoencephalopathies | D056784 | 3 associated lipids |
| Pouchitis | D019449 | 3 associated lipids |
| Granuloma, Giant Cell | D006101 | 7 associated lipids |
| Epstein-Barr Virus Infections | D020031 | 3 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Beysens AJ et al. | FK 506: monitoring in plasma or in whole blood? | 1991 | Transplant. Proc. | pmid:1721263 |
| Grenier FC et al. | A whole blood FK 506 assay for the IMx analyzer. | 1991 | Transplant. Proc. | pmid:1721264 |
| Friob MC et al. | A combined HPLC-ELISA evaluation of FK 506 in transplant patients. | 1991 | Transplant. Proc. | pmid:1721265 |
| Machida M et al. | Effect of temperature and hematocrit on plasma concentration of FK 506. | 1991 | Transplant. Proc. | pmid:1721266 |
| Sigal NH et al. | Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK 506? | 1991 | Transplant. Proc. | pmid:1721295 |
| Bierer BE et al. | FK 506 and rapamycin: molecular probes of T-lymphocyte activation. | 1991 | Transplant. Proc. | pmid:1721296 |
| Tanida I et al. | Yeast cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase associated with the secretory pathway. | 1991 | Transplant. Proc. | pmid:1721297 |
| O'Neill EA et al. | The FK 506-sensitive nature of the interleukin-2 promoter is derived from a specific array of multiple regulatory elements. | 1991 | Transplant. Proc. | pmid:1721298 |
| Didlake R and Grogan J | Effect of FK 506 on rat leukocyte chemotaxis. | 1991 | Transplant. Proc. | pmid:1721327 |
| Hultsch T and Hohman RJ | Categorizing receptor-signaling pathways with FK 506 and rapamycin. | 1991 | Transplant. Proc. | pmid:1721328 |
| Takai K et al. | Immunosuppressive effects of FK 506 on rat lymphoid organs. | 1991 | Transplant. Proc. | pmid:1721329 |
| Ishibashi M et al. | Effect of FK 506 on generation of activated macrophages invading rejected skin allografts in rats: discrepancy of in vitro versus in vivo effects. | 1991 | Transplant. Proc. | pmid:1721330 |
| Schreiber SL | Chemistry and biology of the immunophilins and their immunosuppressive ligands. | 1991 | Science | pmid:1702904 |
| Armitage JM et al. | The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721359 |
| Dew MA et al. | Quality-of-life advantages of FK 506 vs conventional immunosuppressive drug therapy in cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721360 |
| Shapiro R et al. | FK 506 in clinical kidney transplantation. | 1991 | Transplant. Proc. | pmid:1721361 |
| McCauley J et al. | Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. | 1991 | Transplant. Proc. | pmid:1721362 |
| Warty V et al. | Distribution of FK 506 in plasma lipoproteins in transplant patients. | 1991 | Transplant. Proc. | pmid:1703363 |
| Kusne S et al. | Early infections in kidney transplant recipients under FK 506. | 1991 | Transplant. Proc. | pmid:1703364 |
| Doi R et al. | Mechanisms by which FK 506 affects exocrine pancreas in rats. | 1991 | Transplant. Proc. | pmid:1721392 |
| Rilo HL et al. | Effect of FK 506 on function of human islets of Langerhans. | 1991 | Transplant. Proc. | pmid:1721393 |
| Carroll PB et al. | Synexin: a target protein for toxic effects of cyclosporine and FK 506 in endocrine cells. | 1991 | Transplant. Proc. | pmid:1721394 |
| Scantlebury V et al. | New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. | 1991 | Transplant. Proc. | pmid:1721395 |
| Cooper MH et al. | Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506. | 1991 | Transplant. Proc. | pmid:1721421 |
| Yoshimi F et al. | Canine total orthotopic small bowel transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721422 |
| Santiago SF et al. | Effect of donor pretreatment with FK 506 upon small intestine allotransplantation in rats. | 1991 | Transplant. Proc. | pmid:1721423 |
| Murase N et al. | Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. | 1991 | Transplant. Proc. | pmid:1721424 |
| Langrehr JM et al. | Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. | 1991 | Transplant. Proc. | pmid:1721425 |
| Takeda Y et al. | Effect of FK 506 on the survival of rat small bowel allografts. | 1991 | Transplant. Proc. | pmid:1721426 |
| Stevens C et al. | The effects of immunosuppressive agents on in vitro production of human immunoglobulins. | 1991 | Transplantation | pmid:1710843 |
| Metcalfe S and Milner J | Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. | 1991 | Transplantation | pmid:1710844 |
| Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
| Neuberger J | FK 506--a promise of good things to come? | 1991 | Hepatology | pmid:1711005 |
| Fujino Y et al. | FK 506 treatment of experimental autoimmune uveoretinitis in primates. | 1991 | Transplant. Proc. | pmid:1721454 |
| Liversidge J et al. | FK 506 modulates accessory cell adhesion molecule expression and inhibits CD4 lymphocyte adhesion to retinal pigment epithelial cells in vitro: implications for therapy of uveoretinitis. | 1991 | Transplant. Proc. | pmid:1721455 |
| Mochizuki M et al. | A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. | 1991 | Transplant. Proc. | pmid:1721456 |
| Roat MI et al. | Treatment of Cogan's syndrome with FK 506: a case report. | 1991 | Transplant. Proc. | pmid:1721457 |
| Forrest MJ et al. | FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. | 1991 | Biochem. Pharmacol. | pmid:1716098 |
| DiLella AG and Craig RJ | Exon organization of the human FKBP-12 gene: correlation with structural and functional protein domains. | 1991 | Biochemistry | pmid:1716149 |
| Epand RF and Epand RM | The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells. | 1991 | Anticancer Drug Des. | pmid:1714737 |
| McKeon F | When worlds collide: immunosuppressants meet protein phosphatases. | 1991 | Cell | pmid:1716181 |
| Christians U et al. | Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. | 1991 | Clin. Biochem. | pmid:1714802 |
| Petros AM et al. | NMR studies of an FK-506 analogue, [U-13C]ascomycin, bound to FKBP: conformation and regions of ascomycin involved in binding. | 1991 | J. Med. Chem. | pmid:1716684 |
| Turka LA and Thompson CB | Structure-function relationship of immunosuppressive drugs: a cautionary tale. | 1991 | Hepatology | pmid:1714876 |
| Brizuela L et al. | Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. | 1991 | Mol. Cell. Biol. | pmid:1715022 |
| Carroll PB et al. | Effect of the immunosuppressant FK 506 on insulin release from adult rat islets of Langerhans. | 1991 | Transplant. Proc. | pmid:1703688 |
| Sakr MF et al. | Protective effect of FK 506 against hepatic ischemia in rats. | 1991 | Transplant. Proc. | pmid:1703689 |
| Katayama Y et al. | Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation. | 1991 | Transplant. Proc. | pmid:1703690 |
| Thomson AW | The immunosuppressive macrolides FK-506 and rapamycin. | 1991 | Immunol. Lett. | pmid:1717376 |
| Takaya S et al. | Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1703691 |